Author

V. Chi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. K. Chatterjee· 4 shared A. K. Gupta· 4 shared A. K. Woods· 4 shared C. W. McNamara· 3 shared P. G. Schultz· 3 shared S. B. Joseph· 3 shared A. Nazarian· 2 shared F. Weiss· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

A. K. Chatterjee

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Identification of mCMQ069, a novel antimalarial with potential for a single-dose cure and/or 28-day chemoprevention

A. K. Gupta, J. Pedroarena, A. Nazarian, J. Antonova-Koch, F. Weiss, K. Kumpornsin, V. Chi, A. K. Woods, K.-J. Lee, S. B. Joseph, S. Li, J. Brittain, E. D. Hostos, J. Duffy, A. Cooper, , A. K. Chatterjee

This paper identifies mCMQ069, a novel antimalarial with potential for single-dose cure and one-month chemoprevention, showing improved pharmacokinetic properties over KAF156.

bioRxiv · Jul 1, 2024 · PreprintMicrobiology

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection

A. K. Gupta, A. M. Eliasen, W. Andahazy, F. Zhou, K. Henson, V. Chi, A. K. Woods, S. B. Joseph, K. L. Kuhen, J. Wisler, H. Ramachandruni, J. Duffy, J. N. Burrows, E. Vadas, A. Slade, , A. K. Chatterjee

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.

bioRxiv · Feb 8, 2024 · PreprintPharmacology & Toxicology

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection

C.-k. Oh, T. Nakamura, N. Beutler, X. Zhang, J. Pina-Crespo, M. Talantova, S. Ghatak, D. Trudler, L. N. Carnevale, S. R. McKercher, M. A. Bakowski, J. K. Diedrich, A. J. Roberts, A. K. Woods, V. Chi, , S. A. Lipton

This paper develops aminoadamantane nitrate compounds that inhibit SARS-CoV-2 infection by S-nitrosylating ACE2 and blocking viral entry, showing efficacy in vitro and in a Syrian hamster model.

bioRxiv · Apr 5, 2022Microbiology